Revive Therapeutics Ltd., a Canadian health care company operating within the pharmaceutical sector, has been actively engaged in the development and commercialization of cannabinoid-based products. The company is listed on the Canadian National Stock Exchange and trades in Canadian dollars (CAD). As of December 11, 2025, Revive Therapeutics Ltd. closed at a price of CAD 0.015, reflecting a notable decline from its 52-week high of CAD 0.035 on June 9, 2025, and a rise from its 52-week low of CAD 0.005 on December 2, 2025. This price movement indicates a 200% decline from its peak, yet it remains 33% above its lowest point, showcasing significant volatility within a constrained trading range.
The company’s market capitalization stands at CAD 6,278,464, underscoring its position within the health care sector. Revive Therapeutics Ltd. has made significant strides in its research endeavors, particularly with its Phase II-A clinical studies for a product named REV-002. This cannabinoid-based compound, bucillamine, is being developed for the treatment of acute gout flares, marking a pivotal advancement in the company’s portfolio.
In addition to its work on REV-002, Revive Therapeutics Ltd. reported a key update on November 21, 2025, concerning a nerve agent countermeasure study. This study represents another facet of the company’s research initiatives, although it has not yet served as a catalyst for a significant shift in the company’s stock price. The market continues to evaluate the company’s valuation in light of its ongoing research projects and the absence of recent market-moving events.
For further information on Revive Therapeutics Ltd. and its offerings, stakeholders and interested parties are encouraged to visit the company’s website at www.revivethera.com . The company’s focus on cannabinoid-based therapies and its commitment to advancing medical treatments through innovative research remain central to its strategic objectives.
